Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T63239 | FXa-IN-1 | ||
FXa-IN-1 是一种FXa 抑制剂,IC50值为 3 nM,Ki 值为 0.7 nM,表现出较好的口服生物利用度和半衰期 (in vivo),能够用于研究血栓栓塞性疾病。 | |||
T10174 |
5-R-Rivaroxaban
|
Factor Xa | Metabolism |
5-R-Rivaroxaban 是一种 Rivaroxaban 的 R 型对映体。其中 Rivaroxaban 是选择性的Factor Xa(FXa) 抑制剂。 | |||
T4980 |
Betrixaban maleate
|
Factor Xa | Metabolism |
Betrixaban maleate 是一种非维生素 K 口服抗凝剂,其作用是由 Xa 因子的竞争性和可逆抑制作用驱动的。 | |||
T1184 |
Rivaroxaban
BAY 59-7939,利伐沙班 |
Factor Xa; Thrombin | Metabolism; Proteases/Proteasome |
Rivaroxaban (BAY 59-7939) 是高效选择性的凝血因子 Xa (FXa) 直接抑制剂,IC50=0.7 nM,Ki 为 0.4 nM。 | |||
T0372 |
Gabexate mesylate
甲磺酸加贝酯,FOY |
Factor Xa; Serine Protease; Proteasome | Metabolism; Proteases/Proteasome; Ubiquitination |
Gabexate mesylate (FOY) 是一种非抗原的类胰蛋白酶丝氨酸蛋白酶抑制剂。 | |||
T4341 |
Betrixaban
贝曲西班,PRT054021 |
Factor Xa | Metabolism |
Betrixaban (PRT054021) 是一种口服具有活力的选择性factor Xa(fXa) 抑制剂,IC50=1.5 nM。 | |||
T1736 |
Apixaban
阿哌沙班,BMS-562247-01 |
Factor Xa | Metabolism |
Apixaban (BMS-562247-01) 是一种高度选择性,可逆的、口服具有活力的凝血因子 Xa (Factor Xa) 抑制剂,抑制人和兔凝血因子 Xa 的 Ki 分别为 0.08 nM 和 0.17 nM。它可以用于研究各种血栓栓塞疾病。 | |||
T31206 |
Darexaban
YM 150,Darexaban, Tanexaban,YM150 |
Factor Xa | Metabolism |
Darexaban (Tanexaban, YM-150) 是选择性的、口服具有活力的 Xa 因子 (FXa) 抑制剂,IC50=54.6 nM。它对其他相关丝氨酸蛋白酶(如胰蛋白酶、凝血酶和激肽释放酶)具有高选择性。它具有抗凝和抗血栓形成作用。 | |||
T22323 |
Enoxaparin sodium
|
Thrombin | Proteases/Proteasome |
Enoxaparin sodium 是一种低分子量肝素 (LMWH),已获得美国 FDA 批准,可用于医疗管理的 ST 段心肌梗死 (STEMI) 或 STEMI 及随后的经皮冠状动脉介入治疗 (PCI) 患者。它与抗凝血酶结合并增强其作用,并抑制凝血因子 XIa、IXa、Xa 和 IIa(凝血酶),从而防止血栓形成。 | |||
T4076 |
Fondaparinux sodium
Natural heparin pentasaccharide Sodium,Fondaparin sodium,磺达肝素(癸)钠,磺达肝癸钠,SR-90107A,Arixtra |
Factor Xa | Metabolism |
Fondaparinux sodium (SR-90107A) 是抗凝血酶依赖性的 factor Xa 抑制剂。 | |||
T2368 |
Edoxaban Tosylate Monohydrate
DU-176b,DU-176b tosylate Monohydrate,Lixiana,Edoxaban,依度沙班对甲苯磺酸盐一水化合物 |
Factor Xa; Thrombin | Metabolism; Proteases/Proteasome |
Edoxaban Tosylate Monohydrate (DU-176b tosylate Monohydrate) 是口服具有活力的 factor Xa 选择性抑制剂。它是一种抗凝剂,可用于预防中风,是一种凝血酶和凝血因子 IXaβ (FIXa) 的弱抑制剂,对 FXa 的选择性超过 10000 倍。它具有抗血栓形成的特性,可用于血栓栓塞性疾病的研究。 | |||
T29215 |
Zifaxaban
TY 602,TY602,TY-602 |
Factor Xa | Metabolism |
Zifaxaban (TY-602) 是一种具有口服活性、竞争性和选择性的 Xa 因子 (FXa) 抑制剂,对人 FXa 的 IC50 为 11.1 nM。Zifaxaban 的亲和力很高,比其他丝氨酸蛋白酶高 10000 倍以上。Zifaxaban 可用于研究动脉和静脉血栓形成。 | |||
T4690 |
Betrixaban hydrochloride(330942-05-7(free base))
PRT054021 hydrochloride,盐酸贝曲西班 |
Factor Xa | Metabolism |
Betrixaban hydrochloride(330942-05-7(free base)) (PRT054021 hydrochloride) 是一种有效的、选择性的、口服有效的 Xa 因子 (fXa) 抑制剂 (IC50: 1.5 nM)。 | |||
T78215 |
Dechloro Rivaroxaban
|
Factor Xa; Others | Metabolism; Others |
Dechloro Rivaroxaban 是一种具有口服活性和高选择性的 Factor Xa 抑制剂。Dechloro Rivaroxaban 对人体内游离 FXa 的抑制作用显著。Dechloro Rivaroxaban 对凝血酶原以及纤维蛋白相关的 FXa 活性也有抑制效果。 | |||
T2368L |
Edoxaban
Lixiana,依杜沙班 |
Factor Xa; Thrombin | Metabolism; Proteases/Proteasome |
Edoxaban (Lixiana) (DU-176) 是一种选择性的,口服有效的 factor Xa (FXa)抑制剂。Edoxaban 对游离 FXa 和凝血酶原的 Ki 分别为 0.561 nM 和 2.98 nM。Edoxaban 是一种抗凝剂,可用于预防中风。Edoxaban 还是一种凝血酶和凝血因子 IXaβ (FIXa) 的弱抑制剂,Ki 值分别为 6.00 μM 和 41.7 μM,对 FXa 的选择性超过 10000 倍。由于具有抗血栓形成的特性,Edoxaban 可用于预防血栓栓塞性疾病的研究。 | |||
T77373 |
Concizumab
mAb 2021,NN 7415 |
Others | Others |
Concizumab 是一种 抗 TFPI 单克隆抗体 (IgG4 型),可选择性与 TFPI 的 Kunitz 型蛋白酶抑制剂 (KPI) 2 结构域结合,从而阻断该结构域与 FXa 活性位点的相互作用。注射 Concizumab 会使血液中凝血酶增加,可用于于预防和治疗血友病。 | |||
T27318 |
Fidexaban
CI-1031,BX-807834,PD-200022,CI1031,BX807834,ZK-807834 |
Factor Xa | Metabolism |
Fidexaban (CI1031) 是一种新型、强效、选择性和口服活性 Xa 因子抑制剂,在多种测定中均显示出抗血栓活性。 | |||
T27224 |
DX-9065A HCl hydrate
DX9065,DX 9065,DX9065A,DX 9065A,DX-9065A,DX-9065 |
||
DX-9065A is a factor Xa inhibitor. DX-9065a inhibits proinflammatory events induced by factor Xa and gingipains. DX-9065a is a competitive inhibitor of the Spectrozyme FXa (SpFXa) cleavage by both fXa and prothrombinase with similar K(i) values of approxi | |||
T12736 |
Rivaroxaban-d4
BAY 59-7939 D4 |
Factor Xa | Metabolism |
Rivaroxaban D4 is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent,selective and direct inhibitor of Factor Xa (FXa)(IC50:0.7 nM; Ki:0.4 nM). | |||
T16410 |
Otamixaban
FXV673,奥米沙班 |
Others | Others |
Otamixaban(FXV673) is an effective (Ki = 0.5 nM), selective, rapid-acting, competitive, and reversible fXa inhibitor. It also effectively inhibits both free and prothrombinase-bound fXa. | |||
T76619 |
Methoxycarbonyl-D-Nle-Gly-Arg-pNA
|
||
Methoxycarbonyl-D-Nle-Gly-Arg-pNA,这是一种底物,主要用于FIXa (Factors IXa) 和 FXa (Factors Xa)的合成蛋白酶。 | |||
T70110 | CVS-1578 | ||
CVS-1578 is a potent serine protease inhibitor, targeting the S2S3 thrombin and FXa subsites. | |||
T37175 |
Edoxaban impurity 4
|
||
Edoxaban impurity 4, an impurity of Edoxaban (DU-176), is a selective, potent, and orally active inhibitor of factor Xa (FXa), exhibiting Kis of 0.561 nM for free FXa and 2.98 nM for prothrombinase. As an anticoagulant agent, Edoxaban is utilized for stroke prevention[1][2]. | |||
T10527 |
Betrixaban-d6
Betrixaban D6 |
Others | Others |
Betrixaban D6 is a deuterium-labeled Betrixaban. Betrixaban is a selective and orally efficacious FXa inhibitor. | |||
T70184 |
YM-60828 dihydrochloride
|
||
YM-60828 dihydrochloride is a Factor Xa (FXa) inhibitor and anticoagulant used in the treatment of venous thromboembolic disease. | |||
T27514 |
GW-813893
GW813893,GW 813893,GSK813893,GSK-813893,GSK 813893 |
||
GW-813893 is a potent, selective and orally active factor Xa inhibitor. GW813893 inhibited FXa and prothrombinase activity with a Ki of 4.0 nM and 9.7 nM, respectively. | |||
T64126 | Edoxaban hydrochloride | ||
Edoxaban (DU-176b) hydrochloride 是一种高效的、选择性的、口服具有活力的、直接的Factor Xa (FXa) 抑制剂,能够作用于人游离 FXa (Ki: 0.561 nM) 和凝血酶原酶 (Ki: 2.98 nM)。Edoxaban hydrochloride 的选择性是其他凝血蛋白酶的 10000 倍以上。Edoxaban hydrochloride 能够用于研究预防血栓栓塞性疾病。 | |||
T30514 |
BMS-344577
U259PQB19A,UNII-U259PQB19A,CHEMBL570867,BMS 344577 |
||
BMS-344577, a lactam derivative based on arylguanidine, is a potent oral active FXA inhibitor with excellent susceptibility in vitro, good pharmacokinetics, and pharmacodynamics in animal models. | |||
T37176 | Edoxaban impurity 6 | ||
Edoxaban impurity 6 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention[1][2]. [1]. Furugohri T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep;6(9):1542-9.[2]. Mendell J, Lee F, Chen S, The Effe... | |||
T19488 |
O-Desmethyl apixaban sulfate sodium
O-Desmethyl apixaban sulfate sodium (503612-76-8 free base) |
Factor Xa | Metabolism |
O-Desmethyl apixaban sulfate sodium inhibits factor X (FXa) with a Ki of 58 μM,and is a major circulating metabolite of Apixaban in humans. | |||
T12782 |
RWJ-445167
3DP-10017 |
Factor Xa; Thrombin | Metabolism; Proteases/Proteasome |
RWJ-445167 is a thrombin and factor Xa dual inhibitor(Ki of 4.0 nM and 230 nM, respectively), with potent antithrombotic activity. | |||
T39029 |
APC-6860
|
||
APC-6860 is a trypsin-like serine proteases inhibitor with k i values of 0.21, 0.44, 1.5, 16.8, 20, 30 μM for uPA, trypsin, tryptase, tPA, thrombin and factor Xa, respectively. APC-6860 has a selectivity ratio for tPA versus uPA of 80. APC-6860 has k i values of 0.1, 0.082 μM for human and murine urokinases, respectively. APC-6860 can be used for the research of cancer. |